Robert Kralovics
Medizinische Universität Wien
H-index: 62
Europe-Austria
Top articles of Robert Kralovics
Combined effects of clonal hematopoiesis and carotid stenosis on cardiovascular mortality
Journal of the American College of Cardiology
2024/5/7
Cihan Ay
H-Index: 41
Robert Kralovics
H-Index: 40
Effects of Tulp4 deficiency on murine embryonic development and adult phenotype
Microscopy Research and Technique
2024/4
Robert Kralovics
H-Index: 40
Método para avaliar se um paciente sofre de uma malignidade mieloide ou tem tendência a sofrer de uma malignidade mieloide, ácido nucleico, sequência alvo, proteína, vacina …
2024/1/16
P1034: FROM SNAPSHOT TO CONTINUUM: CUMULATIVE TIME IN RESPONSE AS AN EMERGING PROXY FOR THROMBOTIC RISK IN POLYCYTHEMIA VERA
HemaSphere
2023/8/1
Robert Kralovics
H-Index: 40
Phenotypic characterization of disease‐initiating stem cells in JAK2‐ or CALR‐mutated myeloproliferative neoplasms
American Journal of Hematology
2023/5
Genetic basis and molecular profiling in myeloproliferative neoplasms
2023/4/20
Robert Kralovics
H-Index: 40
Secreted mutant calreticulins as rogue cytokines in myeloproliferative neoplasms
Blood
2023/2/23
Discovery of JNJ-88549968, a Novel, First-in-Class CALRmutxCD3 T-Cell Redirecting Antibody for the Treatment of Myeloproliferative Neoplasms
Blood
2023/11/28
Individualized Dosing of Ropeginterferon Alfa-2b Ensures Optimal Response in Patients with Low-Risk Polycythemia Vera (PV)
Blood
2023/11/28
Robert Kralovics
H-Index: 40
Event-free survival in patients with polycythemia vera treated with ropeginterferon alfa-2b versus best available treatment
Leukemia
2023/10
Robert Kralovics
H-Index: 40
Efficacy and safety of long-term ropeginterferon alfa-2b treatment in patients with low-risk and high-risk polycythemia vera (PV)
Blood
2022/11/15
Robert Kralovics
H-Index: 40
Co‐expression of mutated Jak2 and Calr enhances myeloproliferative phenotype in mice without loss of stem cell fitness
American Journal of Hematology
2022/11
Robert Kralovics
H-Index: 40
Mutant calreticulin for the diagnosis of myeloid malignancies
2022/8/11
S196: ropeginterferon alfa-2B achieves patient-specific treatment goals in polycythemia vera: final results from the PROUD-PV/CONTINUATION-PV studies
HemaSphere
2022/6/1
Long-term outcomes of polycythemia vera patients treated with ropeginterferon Alfa-2b
Leukemia
2022/5
Robert Kralovics
H-Index: 40
PD‐L1 overexpression correlates with JAK2‐V617F mutational burden and is associated with 9p uniparental disomy in myeloproliferative neoplasms
American Journal of Hematology
2022/4
Genome-wide association study identifies susceptibility loci for acute myeloid leukemia (vol 13, 2, 2022)
Nature Communications
2019
Polycythemia Vera Patients Respond Better to Ropeginterferon Alfa-2b Than HU/BAT Irrespective of Pretreatment or Mutational Status; Results from 5 Years' Treatment in a …
Blood
2021/11/23
Robert Kralovics
H-Index: 40
High-throughput drug screening identifies the ATR-CHK1 pathway as a therapeutic vulnerability of CALR mutated hematopoietic cells
Blood Cancer Journal
2021/7/31
Robert Kralovics
H-Index: 40
Hematopoietic expression of a chimeric murine‐human CALR oncoprotein allows the assessment of anti‐CALR antibody immunotherapies in vivo
American Journal of Hematology
2021/6
Robert Kralovics
H-Index: 40
Co-Authors
